0001396814-24-000084.txt : 20240613
0001396814-24-000084.hdr.sgml : 20240613
20240613181503
ACCESSION NUMBER: 0001396814-24-000084
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240611
FILED AS OF DATE: 20240613
DATE AS OF CHANGE: 20240613
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SLONIN JONATHAN
CENTRAL INDEX KEY: 0001875723
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 241042486
MAIL ADDRESS:
STREET 1: C/O PACIRA BIOSCIENCES, INC.
STREET 2: 5401 WEST KENNEDY BOULEVARD, SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5401 WEST KENNEDY BOULEVARD
STREET 2: SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
BUSINESS PHONE: 813-553-6680
MAIL ADDRESS:
STREET 1: 5401 WEST KENNEDY BOULEVARD
STREET 2: SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
wk-form4_1718316890.xml
FORM 4
X0508
4
2024-06-11
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001875723
SLONIN JONATHAN
C/O PACIRA BIOSCIENCES, INC.
5401 WEST KENNEDY BOULEVARD, SUITE 890
TAMPA
FL
33609
0
1
0
0
Chief Medical Officer
1
Common Stock
2024-06-11
2024-06-11
4
S
0
5012
28.57
D
44569.475
D
Common Stock
2024-06-12
4
A
0
54300
0
A
98869.475
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
/s/ Kristen Williams, Attorney-in-Fact
2024-06-13